Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

216 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pathologic responses in oligometastatic NSCLC patients treated with neoadjuvant immune checkpoint blockade with and without chemotherapy followed by surgery.
Boch T, Frost N, Sommer L, Overbeck TR, Michaeli CT, Szuszies CJ, Rieckmann LM, Beumer N, Imbusch CD, Winter H, Thomas M, Roeper J, Janning M, Griesinger F, Wermke M, Loges S. Boch T, et al. Among authors: griesinger f. Lung Cancer. 2022 Feb;164:46-51. doi: 10.1016/j.lungcan.2021.11.009. Epub 2021 Nov 23. Lung Cancer. 2022. PMID: 34998106
Recurrence patterns and impact of brain metastases in synchronous single organ oligometastatic lung cancer following local ablative treatment - A multicenter analysis.
Frost N, Roeper J, Velthaus JL, Raspe M, Olive E, Schmittel A, Schmidt B, Wasilewski D, Onken J, Lüders H, Witzenrath M, Senger C, Böhmer D, Loges S, Griesinger F, Modest DP, Grohé C. Frost N, et al. Among authors: griesinger f. Lung Cancer. 2022 Aug;170:165-175. doi: 10.1016/j.lungcan.2022.06.017. Epub 2022 Jul 2. Lung Cancer. 2022. PMID: 35803041
Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing.
Christopoulos P, Kirchner M, Roeper J, Saalfeld F, Janning M, Bozorgmehr F, Magios N, Kazdal D, Volckmar AL, Brückner LM, Bochtler T, Kriegsmann M, Endris V, Penzel R, Kriegsmann K, Eichhorn M, Herth FJF, Heussel CP, El Shafie RA, Schneider MA, Muley T, Meister M, Faehling M, Fischer JR, Heukamp L, Schirmacher P, Bischoff H, Wermke M, Loges S, Griesinger F, Stenzinger A, Thomas M. Christopoulos P, et al. Among authors: griesinger f. Lung Cancer. 2020 Oct;148:105-112. doi: 10.1016/j.lungcan.2020.08.007. Epub 2020 Aug 22. Lung Cancer. 2020. PMID: 32871455
The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions.
Christopoulos P, Kluck K, Kirchner M, Lüders H, Roeper J, Falkenstern-Ge RF, Szewczyk M, Sticht F, Saalfeld FC, Wesseler C, Hackanson B, Dintner S, Faehling M, Kuon J, Janning M, Kauffmann-Guerrero D, Kazdal D, Kurz S, Eichhorn F, Bozorgmehr F, Shah R, Tufman A, Wermke M, Loges S, Brueckl WM, Schulz C, Misch D, Frost N, Kollmeier J, Reck M, Griesinger F, Grohé C, Hong JL, Lin HM, Budczies J, Stenzinger A, Thomas M. Christopoulos P, et al. Among authors: griesinger f. Eur J Cancer. 2022 Jul;170:106-118. doi: 10.1016/j.ejca.2022.04.020. Epub 2022 May 20. Eur J Cancer. 2022. PMID: 35598358
Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany.
Griesinger F, Pérol M, Girard N, Durand-Zaleski I, Zacharias S, Bosquet L, Jänicke M, Quantin X, Groth A, Fleitz A, Calleja A, Patel S, Lacoin L, Daumont MJ, Penrod JR, Carroll R, Waldenberger D, Reynaud D, Thomas M, Chouaid C. Griesinger F, et al. Lung Cancer. 2022 Oct;172:65-74. doi: 10.1016/j.lungcan.2022.08.001. Epub 2022 Aug 6. Lung Cancer. 2022. PMID: 36007281 Free article.
216 results